Park Shin-Hoo, Han Wonshik, Yoo Tae-Kyung, Lee Han-Byoel, Jin Ung Sik, Chang Hak, Minn Kyung Won, Noh Dong-Young
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
J Breast Cancer. 2016 Mar;19(1):68-75. doi: 10.4048/jbc.2016.19.1.68. Epub 2016 Mar 25.
The purpose of this study was to compare locoregional recurrence-free survival (LRFS) and disease-free survival (DFS) between patients undergoing mastectomy and immediate breast reconstruction (IBR) and those undergoing mastectomy alone.
A retrospective review of patients who underwent mastectomy and immediate breast reconstruction for resectable invasive breast cancer between 2002 and 2010 at a single center was conducted. These cases were matched to patients who underwent mastectomy alone in the same time period, performed by 1:2 matching. Matching control variables included age, tumor size, axillary lymph node metastasis, and estrogen receptor status. Overall, 189 patients were identified in the IBR group, and 362 patients were matched to this group.
In the IBR group, 75 patients (39.7%) underwent conventional total mastectomy, 78 (41.3%) underwent skin-sparing mastectomy (SSM), and 36 (19.0%) underwent nipple-sparing mastectomy (NSM). The IBR group was significantly younger than the control group (41.9 and 45.1 years, respectively) (p=0.032), in spite of matching between three age groups. The DFS rates were similar between the IBR group and mastectomy alone group, at 92.0% and 89.9%, respectively, at 5-year follow-up (log-rank test, p=0.496). The 5-year LRFS was 96.2% in the IBR group and 96.4% in the mastectomy alone group (log-rank test, p=0.704), similar to data from previous reports. Subgroup analyses for SSM or NSM patients showed no differences in LRFS and DFS between the two groups. Additionally, in stage III patients, IBR did not cause an increase in recurrence.
IBR after mastectomy, including both SSM and NSM, had no negative impact on recurrence or patient survival, even in patients with advanced disease.
本研究旨在比较接受乳房切除术及即刻乳房重建(IBR)的患者与仅接受乳房切除术的患者之间的局部区域无复发生存期(LRFS)和无病生存期(DFS)。
对2002年至2010年在单一中心因可切除浸润性乳腺癌接受乳房切除术及即刻乳房重建的患者进行回顾性研究。这些病例与同期仅接受乳房切除术的患者按1:2匹配。匹配的对照变量包括年龄、肿瘤大小、腋窝淋巴结转移及雌激素受体状态。总体而言,IBR组共纳入189例患者,362例患者与之匹配。
IBR组中,75例(39.7%)患者接受传统全乳切除术,78例(41.3%)接受保乳皮肤乳房切除术(SSM),36例(19.0%)接受保乳乳头乳房切除术(NSM)。尽管在三个年龄组之间进行了匹配,但IBR组患者明显比对照组年轻(分别为41.9岁和45.1岁)(p = 0.032)。在5年随访时,IBR组和仅行乳房切除术组的DFS率相似,分别为92.0%和89.9%(对数秩检验,p = 0.496)。IBR组的5年LRFS为96.2%,仅行乳房切除术组为96.4%(对数秩检验,p = 0.704),与既往报道数据相似。对SSM或NSM患者的亚组分析显示,两组之间的LRFS和DFS无差异。此外,在III期患者中,IBR并未导致复发增加。
乳房切除术后的IBR,包括SSM和NSM,对复发或患者生存均无负面影响,即使是晚期疾病患者。